Literature DB >> 17098843

Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women.

Deborah R Gustafson1, Ingmar Skoog, Lars Rosengren, Henrik Zetterberg, Kaj Blennow.   

Abstract

BACKGROUND: Low levels of cerebrospinal fluid (CSF) beta-amyloid 1-42 (Abeta42) and high total tau (T-tau) are diagnostic for manifest Alzheimer's disease. It is not known, however, whether these biomarkers may be risk indicators for cognitive decline in otherwise healthy older people.
METHODS: The longitudinal relationship between CSF markers, Abeta42 and T-tau, measured in 1992, and change in Mini-Mental State Examination (deltaMMSE) score between 1992 and 2002 were investigated in 55 women (aged 70-84 years, mean (SD) MMSE score = 28.3 (1.5)), who were participants in the Prospective Population Study of Women in Gothenburg, Sweden. These women did not have dementia when they experienced lumbar puncture in 1992-3.
RESULTS: Over the 8-year follow-up period, deltaMMSE (range = +3 to -21 points) was correlated with Abeta42 (Spearman's r = 0.40, p = 0.002), such that lower levels of Abeta42 were related to greater decline. This was also observed after excluding 4 women who developed dementia between 1992 and 2002 (Spearman's r = 0.34, p = 0.019). A multivariate logistic regression model predicting a decline of > or = 5 points on the MMSE (observed in six women), or a risk of developing dementia over the 8-year follow-up period (observed in four women), including age, education, Abeta42 and T-tau as covariates, showed that Abeta42 was the sole predictor of significant cognitive decline or dementia (OR per 100 pg/ml Abeta42 = 2.24, 95% CI 1.19 to 4.22, p = 0.013).
CONCLUSIONS: Low levels of CSF Abeta42 may predict cognitive decline among older women without dementia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17098843      PMCID: PMC2117838          DOI: 10.1136/jnnp.2006.100529

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  30 in total

1.  CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

Authors:  F H Bouwman; S N M Schoonenboom; W M van der Flier; E J van Elk; A Kok; F Barkhof; M A Blankenstein; Ph Scheltens
Journal:  Neurobiol Aging       Date:  2006-06-19       Impact factor: 4.673

2.  Towards an earlier diagnosis of Alzheimer's disease.

Authors:  E Vanmechelen; H Vanderstichele
Journal:  J Biotechnol       Date:  1998-12-11       Impact factor: 3.307

3.  The study of women in Gothenburg 1968-1969--a population study. General design, purpose and sampling results.

Authors:  C Bengtsson; G Blohmé; L Hallberg; T Hällström; B Isaksson; K Korsan-Bengtsen; G Rybo; E Tibblin; G Tibblin; H Westerberg
Journal:  Acta Med Scand       Date:  1973-04

4.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Authors:  N Andreasen; L Minthon; P Davidsson; E Vanmechelen; H Vanderstichele; B Winblad; K Blennow
Journal:  Arch Neurol       Date:  2001-03

5.  Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.

Authors:  I Skoog; P Davidsson; O Aevarsson; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

6.  CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

Authors:  D Strozyk; K Blennow; L R White; L J Launer
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

Review 7.  CSF markers for incipient Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

8.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Authors:  H Hampel; S J Teipel; T Fuchsberger; N Andreasen; J Wiltfang; M Otto; Y Shen; R Dodel; Y Du; M Farlow; H-J Möller; K Blennow; K Buerger
Journal:  Mol Psychiatry       Date:  2004-07       Impact factor: 15.992

9.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Authors:  D Galasko; L Chang; R Motter; C M Clark; J Kaye; D Knopman; R Thomas; D Kholodenko; D Schenk; I Lieberburg; B Miller; R Green; R Basherad; L Kertiles; M A Boss; P Seubert
Journal:  Arch Neurol       Date:  1998-07

10.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Authors:  K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

View more
  74 in total

1.  Maternal family history is associated with Alzheimer's disease biomarkers.

Authors:  Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  CSF biomarkers for Alzheimer's disease: current utility and potential future use.

Authors:  David M Holtzman
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

3.  CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

Authors:  A Siderowf; S X Xie; H Hurtig; D Weintraub; J Duda; A Chen-Plotkin; L M Shaw; V Van Deerlin; J Q Trojanowski; C Clark
Journal:  Neurology       Date:  2010-08-18       Impact factor: 9.910

4.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Authors:  Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

5.  Use of CSF biomarkers in Alzheimer's disease clinical trials.

Authors:  K Blennow; H Zetterberg
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 6.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

Review 7.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

8.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Authors:  John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

9.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

10.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.